Conclusions : Isoflavone treatments exert a moderately beneficial effect against  estrogen-deficient bone loss in women .
The effect appears dependent on whether isoflavone treatments are in aglycone form ; we conclude that beneficial effects against bone loss may be enhanced for isoflavone aglycones
Background : Age-related estrogen deficiency leads to accelerated bone resorption .
There is evidence that , through selective estrogen receptor modulation , isoflavones may exert beneficial effects against  estrogen-deficient bone loss .
Isoflavone aglycones show higher bioavailability than their glycosidic counterparts and thus may have greater potency .
Objective : To summarize evidence , we executed a systematic review and meta- analysis examining isoflavone therapies and bone mineral density ( BMD ) loss in peri- and postmenopausal women .
Possible role of equol status in the effects of isoflavone on bone and fat mass in postmenopausal Japanese women: a double-blind, randomized, controlled trial
Objective : Equol is more biologically active than its precursor daidzein , which is the principal isoflavone found in soybean . There are interindividual differences in the ability to produce equol ; these may lead to differences in the effects of isoflavone intervention on human health . This study aim ed to investigate whether the effects of soy isoflavones on bone and fat mass are related to an individual 's equol status . Design : We performed a 1-year double-blind , r and omized trial to compare the effects of isoflavone ( 75 mg of isoflavone conjugates/day ) with those of placebo on bone mineral density , fat mass , and serum isoflavone concentrations in early postmenopausal Japanese women who were classified based on their equol-producer phenotype . Results : After 1 year , the isoflavone intervention significantly increased the serum equol concentration in the equol producers but not in the nonproducers . In the isoflavone group , the annualized changes in the bone mineral density of the total hip and intertrochanteric regions were −0.46 % and −0.04 % , respectively , in the equol producers and −2.28 % and −2.61 % , respectively , in the nonproducers ; these values were significantly different ( P < 0.05 for both the regions ) . Significant differences were observed between the equol producers and nonproducers in the isoflavone group with regard to the annualized changes in the fat mass . No significant difference in the annualized changes in bone mineral density and fat mass was observed between the equol producers and nonproducers in the placebo group . Conclusions : Our data suggest that the preventive effects of isoflavones on bone loss and fat accumulation in early postmenopausal women depend on an individual 's equol-producing capacity
Conclusions : Isoflavone treatments exert a moderately beneficial effect against  estrogen-deficient bone loss in women .
The effect appears dependent on whether isoflavone treatments are in aglycone form ; we conclude that beneficial effects against bone loss may be enhanced for isoflavone aglycones
Background : Age-related estrogen deficiency leads to accelerated bone resorption .
There is evidence that , through selective estrogen receptor modulation , isoflavones may exert beneficial effects against  estrogen-deficient bone loss .
Isoflavone aglycones show higher bioavailability than their glycosidic counterparts and thus may have greater potency .
Objective : To summarize evidence , we executed a systematic review and meta- analysis examining isoflavone therapies and bone mineral density ( BMD ) loss in peri- and postmenopausal women .